Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1,550.00p 1,525.00p 1,575.00p 1,550.00p 1,550.00p 1,550.00p 2,268.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.5 4.2 69.2 22.4 79.03

Bioventix Share Discussion Threads

Showing 451 to 475 of 475 messages
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
DateSubjectAuthorDiscuss
24/2/2017
11:40
London Times today reports on a device called Vitalscan that can diagnose a heart attack in 5 mins by measuring the electro-magnetic fluctuations of the heart. Rules out a heart attack in 1/3 patients ultimately found to have no heart condition (means that it is 1/3 effective in patients with suspected heart attach ??)in earlier tests. Now being trialled in 4 NHS A&E depts. Kit costs £100k a pop - but that is now not if adopted I guess. Anyone know more about this ? How does this fit in with the troponin testing ?
housemartin2
22/2/2017
12:12
Too soon it seems ;-)
igbertsponk
13/2/2017
08:28
I've sold out here today. Made 50% in a fairly short time period.
rcturner2
05/2/2017
03:52
Did not see this until searching for some data this weekend: Https://issuu.com/masterinvestormagazine/docs/master_investor_magazine_22 Pages 49 & 50 are of interest to BVXP investors.
lauders
03/2/2017
10:13
Let's hope this move to higher ground is sustainable.
soundsplausible
02/2/2017
13:12
Must be presenting well! Nice ticks up this week.
igbertsponk
29/1/2017
13:10
Just seen BVXP are presenting on Tuesday at the Growth and Innovation show.
valustar1
28/1/2017
00:23
Roche like many of the large diagnostic companies generally develop their own antibodies (usually mice based). Bioventix (sheep) Abcam (owner of Rabmab - Rabbit) whose antibodies are based on larger mammals only get involved when the diagnostic companies need a particular sensitive test (i.e a high degree of specificity).
boros10
27/1/2017
18:37
Boros10 Do you know who makes the monoclonal antibodies for Roche?
tadders2
27/1/2017
17:22
Yes - The £1 target is for the EPS. I reckon we'll get there by 2018/19. Next year will all depend on the timing of Siemen's launch in Europe and whether it has secured FDA clearance (should be a formality now) in the U.S. and the timing of the launch.
boros10
27/1/2017
17:18
Ilovefrogs : well I have never been accused of being "Boris the Bold".
boros10
27/1/2017
12:50
You're right Tads, he did - my bad.
ilovefrogs
27/1/2017
12:06
I think he meant EPS.
tadders2
27/1/2017
11:53
Boros10 - Your prediction of the stock topping £1 is not particularly bold given current price of £14......? We really do need Siemens to get this sorted prior to September or we are going to see a bit of hole in revenues...!
ilovefrogs
20/1/2017
18:32
Who produces the monoclonal antibodies for Roche?
tadders2
20/1/2017
18:27
The test has a very high negative predictive value (absence of troponin means you haven't had a heart attack) but a very low positive predictive value (presence of troponin is only due to a heart attack 5-20% of the time according to Roche press release). Management protocols are needed because the test by itself doesn't tell you much if it's positive. The result needs to be paired with EKG, a second test to determine a trend, patient history etc. to determine how to treat a patient. The FDA has been very concerned about these things and also standardisation of test results. Approval of the Roche test is good news because it means an FDA regime for approval is in place. First step for Bioventix is still Siemens European approval. Siemens investor relations had nothing more interesting to say than they were targeting "CE-marking in 2017".
gsbmba99
20/1/2017
15:52
Boros10, What is so special about the Roche's test that is not in the two have I mentioned earlier? I also note ... "Adoption of high-sensitivity troponin testing is likely to require coupling with management protocols that guide interpretation and care if the benefits of greater diagnostic discrimination are to be harnessed," the study researchers had concluded. ... thus, not without problems.
piedro
20/1/2017
14:09
Thanks Boros10
nfs
20/1/2017
13:46
Great news. The FDA has finally given the green light to the new generation of high sensitivity troponin tests by authorising Roche's Elecsys TnT Gen 5 STAT test. Hopefully others will follow including Bioventix's partner Siemens, who are close to launching its own high sensitivity troponin test in outside of the USA. Troponin is the biggest diagnostic in the world and Siemens were one of the market leaders with its older generation test(which did not include the Bioventix antibody). This augurs very well for Bioventix's revenues and earnings and underpins the growth story. I expect Bioventix's earnings to top £1 per share over the next couple of years once Siemens launches in the US and globally. http://www.medpagetoday.com/cardiology/myocardialinfarction/62620
boros10
16/1/2017
10:53
Thank you ilovefrogs, I had the same impression but if I remember correctly, Bioventix has said that their test would be fast whereas all others {the competition} took more than an hour to complete.
piedro
16/1/2017
09:31
The only troponin test relevant for Bioventix is the Siemens product. I'm not sure it's licensed yet, as I think Bioventix would have told us.
ilovefrogs
16/1/2017
07:07
Something more on Troponin ... One Step Troponin I test The One-Step Troponin I test is a fast in vitro immunochromatographic test. It is designed for qualitative determination of cardiac troponin I (cTnI) in human serum or plasma specimens as an aid in the diagnosis of myocardial infarction. Principle: sample mobilizes gold anti-cTnI conjugate that is coated on the conjugate pad. The mixture moves along the membrane by capillary action and reacts with anti-cTnI antibody that is coated on the test region. - Sensitivity: 1.0ng/ml; - Assays are easy to perform, qualitative results are read visually without any instrument; - No other reagent is needed; - Takes less than 15 minutes to be sure. hTTp://atlaslink-inc.com/rapid_tests_other.html ... is this anyway related with BVXP or part of the competition?
piedro
09/1/2017
17:07
Ta. A clickable version hTTp://www.moneyobserver.com/our-analysis/share-watch-ab-dynamics-bioventix-gattaca-motorpoint-tristel
igbertsponk
09/1/2017
16:14
Money Observer Richard Beddards 5 Tips hxxp://www.moneyobserver.com/our-analysis/share-watch-ab-dynamics-bioventix-gattaca-motorpoint-tristel
martinthebrave
04/1/2017
16:33
Troponin Blood Testing In Cardiac Care http://tinyurl.com/zzf87w5
piedro
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170225 11:38:05